Advanced Patented Generics Services

Through our proprietary SPID®-Technology, we can repurpose, reposition, and relaunch generic APIs with patent protection while also addressing common issues with generic drugs such as patient compliance, dosage, and side effects. Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.